Geode Capital Management’s TRACON Pharmaceuticals TCON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-14,335
Closed -$123K – 4639
2024
Q1
$123K Buy
14,335
+3,896
+37% +$18.6K ﹤0.01% 4098
2023
Q4
$36.6K Sell
10,439
-222
-2% -$781 ﹤0.01% 4421
2023
Q3
$38K Buy
10,661
+2,870
+37% +$15.4K ﹤0.01% 4486
2023
Q2
$45.3K Hold
7,791
– – ﹤0.01% 4524
2023
Q1
$295K Hold
7,791
– – ﹤0.01% 3867
2022
Q4
$232K Sell
7,791
-17
-0.2% -$514 ﹤0.01% 4023
2022
Q3
$260K Hold
7,808
– – ﹤0.01% 4053
2022
Q2
$312K Buy
7,808
+155
+2% +$6K ﹤0.01% 4012
2022
Q1
$402K Buy
7,653
+457
+6% +$23K ﹤0.01% 4056
2021
Q4
$398K Sell
7,196
-91
-1% -$5.81K ﹤0.01% 4161
2021
Q3
$564K Buy
7,287
+396
+6% +$33.5K ﹤0.01% 3974
2021
Q2
$894K Buy
6,891
+1,643
+31% +$227K ﹤0.01% 3661
2021
Q1
$863K Buy
5,248
+1,814
+53% +$349K ﹤0.01% 3614
2020
Q4
$803K Buy
+3,434
New +$478K ﹤0.01% 3432
2019
Q4
– Sell
-488
Closed -$43K – 4237
2019
Q3
$43K Hold
488
– – ﹤0.01% 4082
2019
Q2
$66K Buy
488
+203
+71% +$32.1K ﹤0.01% 4039
2019
Q1
$78K Hold
285
– – ﹤0.01% 3943
2018
Q4
$35K Hold
285
– – ﹤0.01% 4043
2018
Q3
$116K Hold
285
– – ﹤0.01% 3900
2018
Q2
$153K Buy
285
+150
+111% +$79.8K ﹤0.01% 3784
2018
Q1
$62K Hold
135
– – ﹤0.01% 3922
2017
Q4
$90K Hold
135
– – ﹤0.01% 3843
2017
Q3
$85K Hold
135
– – ﹤0.01% 3850
2017
Q2
$64K Sell
135
-9
-6% -$5.49K ﹤0.01% 3918
2017
Q1
$107K Buy
144
+2
+1% +$1.79K ﹤0.01% 3818
2016
Q4
$139K Buy
142
+20
+16% +$22.9K ﹤0.01% 3716
2016
Q3
$165K Hold
122
– – ﹤0.01% 3663
2016
Q2
$106K Hold
122
– – ﹤0.01% 3787
2016
Q1
$170K Hold
122
– – ﹤0.01% 3684
2015
Q4
$225K Buy
122
+24
+24% +$48K ﹤0.01% 3637
2015
Q3
$191K Buy
98
+6
+7% +$14K ﹤0.01% 3695
2015
Q2
$208K Buy
+92
New +$216K ﹤0.01% 3574

Other funds holding TCON

Geode Capital Management's TCON Position: Q2 2024 in Review

Geode Capital Management sold out of TRACON Pharmaceuticals (TCON) in Q2 2024, closing a stake of 14,335 shares — an estimated $123K sold.

Geode Capital Management first reported a position in TCON in Q2 2015 and held it in 32 quarters. The position peaked at $894K in Q2 2021. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.

  • Geode Capital Management reported no remaining TRACON Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Geode Capital Management sold 14,335 TRACON Pharmaceuticals shares in Q2 2024, an estimated $123K.
  • Geode Capital Management first reported a position in TRACON Pharmaceuticals in Q2 2015 and held it in 32 quarters.
  • Geode Capital Management's TRACON Pharmaceuticals position peaked at $894K in Q2 2021.
  • 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals as of Q2 2024.

Based on Geode Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.